MoonLake Immunotherapeutics (MLTX) Current Assets (2020 - 2026)

MoonLake Immunotherapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $396.6 million for Q1 2026.

• In Q1 2026, Current Assets fell 21.65% year-over-year to $396.6 million; the TTM figure through Mar 2026 stood at $396.6 million (down 21.65% YoY), while the FY2025 annual figure was $421.7 million, down 11.09% from the prior year.
• Current Assets was $396.6 million for Q1 2026 at MoonLake Immunotherapeutics, down from $421.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $553.6 million in Q1 2024 to a low of $66.5 million in Q1 2023.
• Historically, Current Assets has averaged $366.8 million across 5 years, with a median of $455.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Current Assets soared 7857.79% in 2022, then sank 42.75% in 2023.
• A 5-year view of Current Assets shows it stood at $76.5 million in 2022, then surged by 572.01% to $514.2 million in 2023, then slipped by 7.76% to $474.3 million in 2024, then declined by 11.09% to $421.7 million in 2025, then retreated by 5.94% to $396.6 million in 2026.
• The last three Current Assets figures came in at $396.6 million (Q1 2026), $421.7 million (Q4 2025), and $411.2 million (Q3 2025), per Business Quant data.